Valeant Pharmaceuticals Intl Inc (VRX): This Company is Set for Newer Heights in the Eye-Care Sector

Page 1 of 2

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been on an acquisition spree. Its latest purchase is Bausch + Lomb in an all-cash deal worth $8.7 billion. The stock of VRX has been rising over the past year and this takeover will increase it further.

Involved Parties

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is the largest publicly traded Canadian drug maker. Headquartered in Montreal, Quebec, this multinational pharmaceutical company specializes in dermatological and neurological treatments that include prescription, non-prescription, and generic drugs.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

The U.S. is its largest market, and its manufacturing sites are spread across Canada, Poland, Brazil, and Mexico. Its strategy is to develop, acquire, and commercialize new products through strategic partnerships and acquisitions of products and companies.

Bausch + Lomb is owned by an investor group led by Warburg Pincus and is best known for its contact lenses, lens care solutions, ophthalmic surgical devices, and eye drugs. The company was set to go public in 2013, but agreed to be acquired by Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

The Acquisition

This is an all cash deal valued at $8.7 billion, and will be completed in the third quarter of 2013. Under the terms of the agreement, unanimously approved by the Board of Directors of both companies, Warburg Pincus will receive $4.5 billion. The other $4.2 billion will settle the outstanding debt of Bausch + Lomb.

Finance for the acquisition will be raised through debt and the issue of new equity worth $1.5 to $2 billion. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s existing ophthalmology business will be integrated with Bausch + Lomb, which will retain their name as a unit of Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Competitors

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is Israel’s top drug company and the global leader in the makers of generic medicines. The company makes generic antibiotics, heart drugs, anti-depressants, etc. and branded pharmaceuticals for Parkinson’s and multiple sclerosis. Generic drugs are cheaper variants of patent-expired-medicines.

H Lundbeck A/S focuses on drugs that treat central nervous system disorders such as Parkinson’s, Alzheimer’s, depression, etc. The company spends around 20% of its revenue on research and development.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s market cap of $32.5 billion, puts it ahead of Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s MV of $25.9 billion. H Lundbeck is more narrowly focused with a market cap of $3.7 billion only. The net income of Valeant is -$130 million, probably due to its acquisitions, while the corresponding figures for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and H Lundbeck are $1.7 billion and $1.1 billion, respectively.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!